A study showed that a recombinant oncolytic poxvirus virus (hIL-7/mIL-12-VV) dually expressing IL-7 and IL-12 completely altered the tumor immune microenvironment by enhancing the inflammatory immune state, showing beneficial systemic anti-tumor efficacy, significantly increasing the sensitivity of solid tumors to systemic anti-PD-1 and anti-CTLA4. Here, CTLA4 is linked to neoplasm.